Frontlight ResearchEarly access
CompletedNo phase
A Clinical Trial to Evaluate the Safety and Efficacy of an Implantable Wireless Brain-Computer Interface(BCI)System NEO in Patients With Tetraplegia
Key facts
- Who runs it
- Neuracle Medical Technology(Shanghai) Co.,Ltd.
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 32 people enrolled
- Started
- 28 May 2025
- Ended
- 10 Jan 2026
- Type of study
- Interventional
- Treatments tested
- NEO
- Record updated
- 25 August 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Age between 18 and 65 years old, no restriction on gender
- Tetraplegia caused by cervical spinal cord injury
- Score of ≤1 on either the ball grasp or water pouring tasks of the ARAT (Action Research Arm Test)
- Muscle strength of finger flexors < grade 3 according to ISNCSCI (International Standards for Neurological Classification of Spinal Cord Injury)
- Score of ≥2 for "hand to mouth" on ARAT; scores of ≥1 for both "hand to top of head" and "hand to behind the head."
- Neurological assessment indicates normal function of the motor-related cortex, with no significant structural lesions or functional disorders identified
- Diagnosis confirmed for at least 12 months, with a stable condition for at least 6 months following standard treatment
- Normal cognitive function, good compliance, and voluntarily agrees to participate in the clinical trial
Who cannot take part
- Received botulinum toxin injections in the upper limb, neck, or hand within 6 months prior to enrollment, or received stem cell therapy within 1 year
- Any unstable or significant medical condition that may interfere with study procedures or confound the evaluation of study endpoints, such as depression, mood disorders, or other cognitive impairments
- Diagnosed with severe, unstable, and uncontrolled complex regional pain syndrome
- Autoimmune-mediated spinal cord dysfunction/injury
- History of other neurological disorders, such as stroke, multiple sclerosis, traumatic brain injury, or drug-resistant epilepsy
- High risk of surgical complications, such as active systemic infection, coagulation disorders (e.g., receiving anticoagulant therapy), or platelet count below 50,000
- Without the consent of the patient or the patient's legal guardian
- Presence of syringomyelia, severe neuropathic pain, or severe spasticity that limits the participant's ability to engage in training
- Requires ventilator support
- Baclofen dosage >30 mg/day
- Patients who have already been implanted with medical devices that deliver electrical energy to the central nervous system
- Peripheral neuropathies (e.g. diabetic polyneuropathy, compressive neuropathies)
- In the investigator's opinion, the study is unsafe or inappropriate for the participant, or the participant is unlikely to comply with the study follow-up schedule
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the safety and efficacy of a Minimally Invasive Wireless Implantable Brain-Computer Interface (BCI) System NEO in patients with tetraplegia and to provide a basis for product registration.
Read full original descriptionShow less
Through brain-computer interface alternative technology, patients can control the external equipment with brain signals to improve the patient's quality of life.
The group in the trial
- Treatment groupTreatment being tested
a Minimally Invasive Wireless Implantable Brain-Computer Interface (BCI) System NEO
Treatment: NEO
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multi-Center Clinical Trial to Evaluate the Safety and Efficacy of an Implantable Wireless Brain-Computer Interface(BCI)System NEO in Patients With Tetraplegia
- Record updated
- 25 August 2026